[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652350":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":30,"centralContacts":34,"locations":44,"responsibleParty":61,"collaborators":65,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":24,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":24,"enrollmentInfo":78,"targetDuration":24,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":93,"whyStopped":24,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"University of Alabama at Birmingham","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Psilocybin, Dose A","EXPERIMENTAL","Single oral dose during an 8-hour supervised session (Specific dose withheld during conduct).",[13,14],"Drug: Psilocybin (single oral capsule administered at one of two dose levels, Dose A or Dose B; specific doses withheld during conduct).","Behavioral: Manualized cognitive behavioral therapy platform (2 preparation + 2 integration sessions).",{"label":16,"type":10,"description":11,"interventionNames":17},"Psilocybin, Dose B",[13,14],[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Psilocybin (single oral capsule administered at one of two dose levels, Dose A or Dose B; specific doses withheld during conduct).","The specific doses (in mg) are intentionally omitted from this registration during the conduct of the trial to preserve masking and reduce expectancy effects. The doses will be disclosed when results are reported after primary completion, by which point participants have been debriefed.",[9,16],null,{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":24},"BEHAVIORAL","Manualized cognitive behavioral therapy platform (2 preparation + 2 integration sessions).","Manualized CBT, adapted from Hendricks et al. (2026; https:\u002F\u002Fjamanetwork.com\u002Fjournals\u002Fjamanetworkopen\u002Ffullarticle\u002F2848757)",[9,16],[31],{"name":32,"affiliation":5,"role":33},"Peter S Hendricks, PhD","PRINCIPAL_INVESTIGATOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":24,"email":39},"Seher Premani, MPH","CONTACT","205-975-7721","spremani@uab.edu",{"name":41,"role":37,"phone":42,"phoneExt":24,"email":43},"Noah Sweat, BS","205-996-0212","nsweat@uabmc.edu",[45],{"facility":5,"status":24,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Birmingham","Alabama","35294","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-86.80249,33.52066,{"lat":55,"lon":54},[58,59,60],{"name":36,"role":37,"phone":38,"phoneExt":24,"email":39},{"name":41,"role":37,"phone":42,"phoneExt":24,"email":43},{"name":32,"role":33,"phone":24,"phoneExt":24,"email":24},{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"SPONSOR_INVESTIGATOR","Peter Hendricks","University Professor and Heersink Endowed Chair",[66],{"name":67,"class":68},"National Institute on Drug Abuse (NIDA)","NIH","100652350","phase-2-psilocybin-for-methamphetamine-use-disorder-100652350",false,"NCT07774702","Psilocybin for Methamphetamine Use Disorder","Psilocybin in the Treatment of Methamphetamine Use Disorder","Inclusion Criteria:\n\n* Age 18+\n* DSM-5 moderate or severe Methamphetamine Use Disorder\n* Severity of Dependence Scale score ≥ 4\n* Methamphetamine use on more than 7 of the past 30 days and more than one positive urine test before randomization\n* A goal of complete abstinence on the Thoughts About Abstinence questionnaire\n* Able to read, write, and speak English\n* A friend or family member available for post-session release\n* Good general health by history and physical\n* Confirmed pre-dose abstinence of at least 24 hours (clinically assessed)\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding, or not using effective contraception\n* Current psychiatric diagnoses other than a mild substance use disorder or tobacco\u002Fnicotine use disorder\n* Current hypertension (\\>140\u002F90 at rest)\n* Regular use of centrally acting serotonergic medications or MAO inhibitors (washout\u002Fre-screen permitted)\n* Personal history of any psychotic or bipolar I\u002FII disorder, or a first- or second-degree relative with such\n* Current suicidal or homicidal ideation\n* Plan to relocate within 6 months\n* Psychedelic use in the past 3 years, more than 3 lifetime psychedelic occasions, more than 3 lifetime ketamine or MDMA occasions, or any prior 5-MeO-DMT or ibogaine use","ALL","18 Years",{"count":79,"type":80},42,"ESTIMATED","INTERVENTIONAL",[83],"PHASE2","This trial tests whether psilocybin-assisted treatment can help adults stop using methamphetamine. Participants receive a single oral dose of psilocybin during a supervised session, paired with brief cognitive behavioral therapy, and are followed for up to six months. The study is supported by the HEAL Initiative (https:\u002F\u002Fwww.nih.gov\u002Fheal).",[86],"Methamphetamine Use Disorder",[88,89,90,91,92],"psilocybin","methamphetamine","HEAL Initiative","psychedelic-assisted therapy","substance use disorder","NOT_YET_RECRUITING","2026-08-17",{"date":96,"type":97},"2026-08-19","ACTUAL",{"date":99,"type":80},"2027-02-01",{"date":101,"type":80},"2032-02-01",{"name":63,"class":6},1]